# Phase 4 Crohn Disease trials recruiting: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 4 for Crohn Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 Crohn Disease trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/crohn-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925450 | Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's Disease | Weill Medical College of Cornell University | Phase 4 | Recruiting | Crohn's Disease, Iron Deficiency Anemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925450) |
| October 13, 2026 | NCT07872449 | Risankizumab for Refractory Perianal Fistulizing Crohn's Disease | Sponsor not shown (see the record) | Phase 4 | Recruiting | Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872449) |
| August 24, 2026 | NCT07782021 | MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease | Icahn School of Medicine at Mount Sinai | Phase 4 | Not yet recruiting | Crohn's Disease, Perianal Fistula | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782021) |
| July 8, 2026 | NCT07691138 | Stopping PPI Therapy in Inactive IBD | University of Nottingham | Phase 4 | Recruiting | Ulcerative Colitis (UC), Crohn's Disease | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691138) |
| June 23, 2026 | NCT07663526 | Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | Recruiting | Crohn's Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663526) |
| June 17, 2026 | NCT07654751 | A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | Janssen Research & Development, LLC | Phase 4 | Recruiting | Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654751) |
| June 1, 2026 | NCT07616687 | Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Phase 4 | Recruiting | Crohn Disease (CD), Intensification | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616687) |
| April 3, 2026 | NCT07510191 | TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 4 | Recruiting | Crohn Disease (CD) | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510191) |
| February 18, 2026 | NCT07417696 | Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease | Chinese Medical Association | Phase 4 | Not yet recruiting | Crohn's Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417696) |
| February 17, 2026 | NCT07415473 | Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease | Chinese Medical Association | Phase 4 | Not yet recruiting | Crohn's Diseases | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415473) |
| December 30, 2025 | NCT07310095 | A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | Xian-Janssen Pharmaceutical Ltd. | Phase 4 | Recruiting | Crohn Disease | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310095) |
| December 26, 2025 | NCT07303686 | De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 | Recruiting | Crohn Disease (CD), Ulcerative Colitis (UC) | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303686) |
| December 18, 2025 | NCT07292012 | Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Phase 4 | Recruiting | Crohn Disease (CD) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292012) |
| November 21, 2025 | NCT07240649 | Emerging Indications for Hyperbaric Oxygen Treatment | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis, Frostbite, Acute COVID-19, Pyoderma... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240649) |
| October 14, 2025 | NCT07216014 | Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 4 | Recruiting | Crohn's Disease and Ulcerative Colitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216014) |
| July 10, 2025 | NCT07059130 | Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059130) |
| May 31, 2025 | NCT06997965 | Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | Alimentiv Inc. | Phase 4 | Recruiting | Crohn Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06997965) |
| September 3, 2024 | NCT06581328 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | Takeda | Phase 4 | Recruiting | Ulcerative Colitis, Crohn's Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06581328) |
| July 25, 2024 | NCT06520397 | Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 4 | Recruiting | Crohn Disease | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06520397) |
| March 7, 2024 | NCT06298461 | Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease. | University of Manitoba | Phase 4 | Recruiting | Crohn Disease, Ulcerative Colitis | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298461) |
| February 14, 2024 | NCT06257706 | VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease | Alimentiv Inc. | Phase 4 | Recruiting | Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06257706) |
| December 22, 2023 | NCT06180382 | Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker... | Centre Hospitalier Universitaire de Saint Etienne | Phase 4 | Recruiting | Crohn's Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06180382) |
| November 2, 2023 | NCT06113913 | Subcutaneous Infliximab After A Previous Intravenous Dose Optimization | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Phase 4 | Recruiting | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06113913) |
| September 22, 2023 | NCT06051253 | TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease | Asan Medical Center | Phase 4 | Recruiting | Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease, Therapeutic Drug Monitoring, Magnetic Resonance... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06051253) |
| July 3, 2023 | NCT05928039 | PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease | University of Calgary | Phase 4 | Recruiting | Crohn Disease | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05928039) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sixth Affiliated Hospital, Sun Yat-sen University | 3 |
| Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2 |
| Chinese Medical Association | 2 |
| Alimentiv Inc. | 2 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | 1 |
| [Xian-Janssen Pharmaceutical Ltd.](https://specstream.ai/data/clinical-trials/company/xian-janssen-pharmaceutical-ltd) | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| University of Manitoba | 1 |
| Asan Medical Center | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 1 |
| Weill Medical College of Cornell University | 1 |
| University of Nottingham | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | 1 |
| Children's Hospital of Fudan University | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| University of Calgary | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 7 |
| United States | 7 |
| Canada | 5 |
| France | 4 |
| Belgium | 3 |
| Italy | 2 |
| United Kingdom | 2 |
| Japan | 1 |
| South Korea | 1 |
| Australia | 1 |
| Czechia | 1 |
| Denmark | 1 |
| Germany | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Portugal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
